Patents Assigned to Scinopharm Taiwan, Ltd.
  • Patent number: 8742143
    Abstract: A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8?): to the prostaglandin analogue, wherein R3 represents hydrogen or a hydroxyl protecting group.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: June 3, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian P. Henschke, Yuanlian Liu, Yung-Fa Chen, Dechao Meng, Ting Sun
  • Patent number: 8735611
    Abstract: The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8b, C9 and C9p.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: May 27, 2014
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, TsungYu Hsiao, MengFen Ho, YuanChang Huang
  • Patent number: 8722900
    Abstract: The present invention relates to processes for making cabazitaxel, cabazitaxel analogues and intermediates thereof. The invention provides novel compounds useful in the synthesis of cabazitaxel.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: May 13, 2014
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: TsungYu Hsiao, Julian Paul Henschke, HsinChang Tseng
  • Publication number: 20140128595
    Abstract: The present invention provides processes for stereoselectively preparing C-arylglucosides that can be useful as synthetic building block or drugs, including SGLT2 inhibitors.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 8, 2014
    Applicant: ScinoPharm Taiwan, LTD.
    Inventors: Julian Paul Henschke, Chen-Wei Lin, Ping-Yu Wu, Chi-Nung Hsiao, Jyh-Hsiung Liao, Tsung-Yu Hsiao
  • Patent number: 8710221
    Abstract: A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: April 29, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Yung-Fa Chen, Julian Paul Henschke, Xiaoheng Zhang, YiJing Chen, ChunFang Xu, Yong Mu
  • Publication number: 20140045926
    Abstract: The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8b, C9 and C9p.
    Type: Application
    Filed: August 12, 2013
    Publication date: February 13, 2014
    Applicant: ScinoPharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, TsungYu Hsiao, MengFen Ho, YuanChang Huang
  • Patent number: 8648188
    Abstract: A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R4 is independently a hydroxy protecting group, OR6 is a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: February 11, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Lijun Mei, Yung-Fa Chen
  • Patent number: 8642327
    Abstract: A method for screening cells with high level expression of a target protein is disclosed. The method includes introducing into a plurality of host cells a DNA construct that encodes both a target protein and an inhibitor to an endogenous selectable marker in the host cells, screening host cells harboring the DNA construct for the expression of the endogenous selectable marker, and isolating cells with reduced expression of the selectable marker. Also disclosed is a DNA construct configured to express both the target protein and the inhibitor inside the host cell.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: February 4, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Wei-Kuang Liu, Min-Pey Ding
  • Patent number: 8643274
    Abstract: The present invention provides for a method of characterizing and classifying a sample containing a complex molecule, such as a peptide or polypeptide mixture, protein, protein mixture, biologic and biosimilar by using physical analysis, such as mass spectrometry, and statistic methods.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: February 4, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Hardy Chan, Jentaie Shiea
  • Publication number: 20140024829
    Abstract: A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.
    Type: Application
    Filed: September 18, 2013
    Publication date: January 23, 2014
    Applicant: SCINOPHARM TAIWAN, LTD.
    Inventors: Yung-Fa CHEN, Julian Paul HENSCHKE, Xiaoheng ZHANG, YiJing CHEN, ChunFang XU, Yong MU
  • Patent number: 8586729
    Abstract: A method for producing a ?-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabine of formula I; and b) quenching the reaction mixture of step a) with a base. The ?-enriched protected decitabine so made may be deprotected to produce a decitabine product in a high yield and purity.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 19, 2013
    Assignee: Scinopharm Taiwan Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Jianbo Yu, Kun Hu, Lijun Mei
  • Patent number: 8575373
    Abstract: The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8b, C9 and C9p.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 5, 2013
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, TsungYu Hsiao, MengFen Ho, YuanChang Huang
  • Patent number: 8563719
    Abstract: The present invention provides a process for making lapatinib and its pharmaceutically acceptable salt by use of new intermediates. A new process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate is also provided.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: October 22, 2013
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Yung-Fa Chen, Julian Paul Henschke, Yuanlian Liu, Guodong Chu, Xiaoheng Zhang
  • Publication number: 20130237487
    Abstract: The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.
    Type: Application
    Filed: October 30, 2012
    Publication date: September 12, 2013
    Applicant: Scinopharm Taiwan, LTD.
    Inventors: Julian Paul Henschke, Meng-Fen Ho, Shu-Ping Chen, Yung-Fa Chen
  • Publication number: 20130211128
    Abstract: A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8?): to the prostaglandin analogue, wherein R3 represents hydrogen or a hydroxyl protecting group.
    Type: Application
    Filed: March 27, 2013
    Publication date: August 15, 2013
    Applicant: SCINOPHARM TAIWAN LTD.
    Inventors: Julian P. HENSCHKE, Yuanlian LIU, Yung-Fa CHEN, Dechao MENG, Ting SUN
  • Patent number: 8497374
    Abstract: A synthetic process for producing bortezomib comprising converting racemic boronic esters, such as the pinacol ?-aminoboronic ester, into mixtures of diastereomers [6] by reaction with a suitably protected L-phenylalanine derivative (see Scheme 3), such as N—BOC-L-phenylalanine. The protecting group of the L-phenylalanine moiety is then removed, such as by reacting the diastereomers [6] with an acid, such as hydrochloric acid, to form a mixture of amine salt diastereomers [7] which is then subjected to conditions under which the desired diastereomer (R,S)-[7] is selectively isolated, such as by crystallization, chromatography or stereoselective hydrolysis. The separated desired diastereomer (R,S)-[7] is then converted into bortezomib or bortezomib anhydride.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: July 30, 2013
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, Aiping Xie, Xin Yan Huang, Yung Fa Chen
  • Patent number: 8497630
    Abstract: The present invention provides for a method of characterizing and classifying a sample of peptide or polypeptide mixtures or a biomolecule comprising a polypeptide component by using mass spectrometry and statistic methods for analyzing the mass spectrometry results.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: July 30, 2013
    Assignee: Scinopharm Taiwan Ltd.
    Inventors: Hardy Chan, Jentaie Shiea, Yi-Tzu Cho, Chi-Hsien Lin
  • Publication number: 20130190512
    Abstract: The present invention provides for synthetic processes for the making of substituted 3-((pyrrol-2-yl)methylene)-2-pyrrolones, including sunitinib. The present invention also provides for a process of crystallizing substantially pure sunitinib L-malate.
    Type: Application
    Filed: November 1, 2010
    Publication date: July 25, 2013
    Applicant: SCINOPHARM TAIWAN, LTD.
    Inventors: Julian P. Henscheke, Yung-Fa Chen
  • Patent number: 8481728
    Abstract: A process of making entecavir comprising converting a compound of formula (M5) to entecavir, wherein the two PGs on the formula (M5) are taken together to form an optionally substituted six- or seven-member cyclic ring.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: July 9, 2013
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Tsung-Cheng Hu, Hung-Tsung Huang
  • Publication number: 20130150574
    Abstract: The present invention provides efficient and economical methods for synthesis of (?)-2-exo-morpholinoisoborne-10-thiol, its enantiomer, and related chiral catalysts. Novel compounds and methods of asymmetric synthesis are also disclosed.
    Type: Application
    Filed: November 29, 2012
    Publication date: June 13, 2013
    Applicant: Scinopharm Taiwan, LTD.
    Inventor: Scinopharm Taiwan, LTD.